

# Oklahoma Health Care Authority

Drug Utilization Review Board

(DUR Board)

Meeting – July 13, 2022 @ 4:00pm

at the

Oklahoma Health Care Authority (OHCA)

4345 N. Lincoln Blvd.

Oklahoma City, Oklahoma 73105

**NOTE:**     ***The DUR Board will meet at 4:00pm at OHCA (see address above). There will be Zoom access to this meeting; however, Zoom access will be set up in view-only mode with no voting, speaking, video, or chat box privileges. Zoom access will allow for viewing of the presentation slides as well as audio of the presentations and discussion during the meeting; however, the DUR Board meeting will not be delayed or rescheduled due to any technical issues that may arise.***

## **AGENDA**

Discussion and action on the following items:

Items to be presented by Dr. Muchmore, Chairman:

### **1. Call to Order**

A. Roll Call – Dr. Wilcox

### **DUR Board Members:**

Dr. Stephen Anderson –	participating in person
Dr. Jennifer de los Angeles –	participating in person
Ms. Jennifer Boyett –	participating in person
Dr. Megan Hanner –	participating in person
Dr. Lynn Mitchell –	participating in person
Dr. John Muchmore –	participating in person
Dr. Lee Muñoz –	participating in person
Dr. James Osborne –	participating in person

### **Viewing Access Only via Zoom:**

Please register for the meeting at:

[https://zoom.us/webinar/register/WN\\_73z8ERX7Sv-KeQGP3GVqPg](https://zoom.us/webinar/register/WN_73z8ERX7Sv-KeQGP3GVqPg)

After registering, you will receive a confirmation email containing information about joining the webinar.

Or join by phone:

Dial: +1-602-753-0140 or +1-669-219-2599

Webinar ID: 952 7560 1667

Passcode: 69395211

## **Public Comment for Meeting:**

- Speakers who wish to sign up for public comment at the OHCA DUR Board meeting may do so in writing by visiting the DUR Board page on the OHCA website at [www.oklahoma.gov/ohca/about/boards-and-committees/drug-utilization-review/dur-board](http://www.oklahoma.gov/ohca/about/boards-and-committees/drug-utilization-review/dur-board) and completing the [Speaker Registration Form](#). Completed Speaker Registration forms should be submitted to [DURPublicComment@okhca.org](mailto:DURPublicComment@okhca.org). Forms must be received after the DUR Board agenda has been posted and no later than 24 hours before the meeting.
- The DUR Board meeting will allow public comment and time will be limited to 40 minutes total for all speakers during the meeting. Each speaker will be given 5 minutes to speak at the public hearing. If more than 8 speakers properly request to speak, time will be divided evenly.
- Only 1 speaker per manufacturer will be allowed.
- Any speakers who sign up for public comment must attend the DUR Board meeting in person at OHCA (see above address). Public comment through Zoom will not be allowed for the DUR Board meeting.

Items to be presented by Dr. Muchmore, Chairman:

### **2. Public Comment Forum**

- A. Acknowledgement of Speakers for Public Comment

Items to be presented by Dr. Muchmore, Chairman:

### **3. Action Item – Approval of DUR Board Meeting Minutes – See Appendix A**

- A. June 8, 2022 DUR Board Meeting Minutes
- B. June 8, 2022 DUR Board Recommendations Memorandum

Items to be presented by Dr. O'Halloran, Dr. Travers, Dr. Muchmore, Chairman:

### **4. Update on Medication Coverage Authorization Unit/Chronic Medication Adherence (CMA) Program Update – See Appendix B**

- A. Pharmacy Helpdesk Activity for June 2022
- B. Medication Coverage Activity for June 2022
- C. CMA Program Update

Items to be presented by Dr. Travers, Dr. Muchmore, Chairman:

### **5. Action Item – Vote to Prior Authorize Xelstrym™ (Dextroamphetamine Transdermal System) and Update the Approval Criteria for the Attention-Deficit/Hyperactivity Disorder (ADHD) and Narcolepsy Medications – See Appendix C**

- A. Market News and Updates
- B. Xelstrym™ (Dextroamphetamine Transdermal System) Product Summary
- C. College of Pharmacy Recommendations

Items to be presented by Dr. Ha, Dr. Muchmore, Chairman:

**6. Action Item – Vote to Prior Authorize Livtency™ (Maribavir) – See Appendix D**

- A. Market News and Updates
- B. Livtency™ (Maribavir) Product Summary
- C. College of Pharmacy Recommendations

Items to be presented by Dr. Ha, Dr. Muchmore, Chairman:

**7. Action Item – Vote to Prior Authorize Quviviq™ (Daridorexant) and Update the Approval Criteria for the Insomnia Medications – See Appendix E**

- A. Market News and Updates
- B. Quviviq™ (Daridorexant) Product Summary
- C. College of Pharmacy Recommendations

Items to be presented by Dr. O'Halloran, Dr. Muchmore, Chairman:

**8. Action Item – Vote to Prior Authorize Invega Hafyera™ (Paliperidone Palmitate Injection) and Update the Approval Criteria for the Atypical Antipsychotic Medications – See Appendix F**

- A. Market News and Updates
- B. Invega Hafyera™ (Paliperidone Palmitate) Product Summary
- C. College of Pharmacy Recommendations

Items to be presented by Dr. O'Halloran, Dr. Muchmore, Chairman:

**9. Action Item – Vote to Prior Authorize Ryplazim® (Plasminogen, Human-tvmh) – See Appendix G**

- A. Market News and Updates
- B. Ryplazim® (Plasminogen, Human-tvmh) Product Summary
- C. College of Pharmacy Recommendations

Items to be presented by Dr. Chandler, Dr. Muchmore, Chairman:

**10. Action Item – Vote to Prior Authorize Citalopram Capsule, Dartisla ODT™ (Glycopyrrolate Orally Disintegrating Tablet), Fleqsuvy™ (Baclofen Oral Suspension), Lofena™ (Diclofenac Potassium Tablet), Loreev XR™ (Lorazepam Extended-Release Capsule), Norliqva® (Amlodipine Besylate Oral Solution), Seglentis® (Celecoxib/Tramadol Tablet), Sutab® (Sodium Sulfate/Magnesium Sulfate/Potassium Chloride Tablet), Tarpeyo™ (Budesonide Delayed-Release Capsule), Vuity™ (Pilocarpine 1.25% Ophthalmic Solution), and Xipere™ (Triamcinolone Acetonide Injection) – See Appendix H**

- A. Introduction
- B. Product Summaries and College of Pharmacy Recommendations

Items to be presented by Dr. Borders, Dr. Muchmore, Chairman:

**11. Action Item – Vote to Prior Authorize Camcevi™ (Leuprolide), Pluvicto® (Lutetium Lu 177 Vipivotide Tetraxetan), Tivdak® (Tisotumab Vedotin-tftv), and Welireg™ (Belzutifan) and Update the Approval Criteria for the Genitourinary and Cervical/Endometrial Cancer Medications – See Appendix I**

- A. Market News and Updates
- B. Product Summaries
- C. College of Pharmacy Recommendations

Items to be presented by Dr. Borders, Dr. Muchmore, Chairman:

**12. Annual Review of Colorectal Cancer Medications and 30-Day Notice to Prior authorize Alymsys® (Bevacizumab-maly), Lonsurf® (Trifluridine/Tipiracil), and Stivarga® (Regorafenib) – See Appendix J**

- A. Introduction
- B. Current Prior Authorization Criteria
- C. Utilization of Colorectal Cancer Medications
- D. Prior Authorization of Colorectal Cancer Medications
- E. Market News and Updates
- F. Product Summaries
- G. College of Pharmacy Recommendations
- H. Utilization Details of Colorectal Cancer Medications

Items to be presented by Dr. Borders, Dr. Muchmore, Chairman:

**13. Annual Review of Danyelza® (Naxitamab-gqqk), Koselugo® (Selumetinib), Pemazyre® (Pemigatinib), Qinlock™ (Ripretinib), and Truseltiq™ (Infigratinib)– See Appendix K**

- A. Introduction
- B. Current Prior Authorization Criteria
- C. Utilization of Danyelza® (Naxitamab-gqqk), Koselugo® (Selumetinib), Pemazyre® (Pemigatinib), Qinlock™ (Ripretinib), and Truseltiq™ (Infigratinib)
- D. Prior Authorization of Danyelza® (Naxitamab-gqqk), Koselugo® (Selumetinib), Pemazyre® (Pemigatinib), Qinlock™ (Ripretinib), and Truseltiq™ (Infigratinib)
- E. Market News and Updates
- F. College of Pharmacy Recommendations
- G. Utilization Details of Danyelza® (Naxitamab-gqqk), Koselugo® (Selumetinib), Pemazyre® (Pemigatinib), Qinlock™ (Ripretinib), and Truseltiq™ (Infigratinib)

Items to be presented by Dr. O'Halloran, Dr. Muchmore, Chairman:

**14. Annual Review of Alzheimer's Disease Medications and 30-Day Notice to Prior Authorize Adlarity® (Donepezil Transdermal System) and Aduhelm™ (Aducanumab-avwa) – See Appendix L**

- A. Current Prior Authorization Criteria
- B. Utilization of Alzheimer's Disease Medications
- C. Prior Authorization of Alzheimer's Disease Medications

- D. Market News and Updates
- E. Aduhelm™ (Aducanumab-avwa) Product Summary
- F. College of Pharmacy Recommendations
- G. Utilization Details of Alzheimer's Disease Medications

Items to be presented by Dr. Chandler, Dr. Muchmore, Chairman:

**15. Annual Review of Testosterone Products and 30-Day Notice to Prior Authorize Tlando® (Testosterone Undecanoate) – See Appendix M**

- A. Current Prior Authorization Criteria
- B. Utilization of Testosterone Products
- C. Prior Authorization of Testosterone Products
- D. Market News and Updates
- E. Cost Comparison
- F. College of Pharmacy Recommendations
- G. Utilization Details of Testosterone Products

Items to be presented by Dr. Ha, Dr. Muchmore, Chairman:

**16. Annual Review of Various Systemic Antibiotics – See Appendix N**

- A. Current Prior Authorization Criteria
- B. Utilization of Various Systemic Antibiotics
- C. Prior Authorization of Various Systemic Antibiotics
- D. Market News and Updates
- E. College of Pharmacy Recommendations
- F. Utilization Details of Various Systemic Antibiotics

Items to be presented by Dr. Ha, Dr. Muchmore, Chairman:

**17. Annual Review of Isturisa® (Osilodrostat) and 30-Day Notice to Prior Authorize Recorlev® (Levoketoconazole) – See Appendix O**

- A. Current Prior Authorization Criteria
- B. Utilization of Isturisa® (Osilodrostat)
- C. Prior Authorization of Isturisa® (Osilodrostat)
- D. Market News and Updates
- E. Recorlev® (Levoketoconazole) Product Summary
- F. College of Pharmacy Recommendations

Items to be presented by Dr. O'Halloran, Dr. Muchmore, Chairman:

**18. U.S. Food and Drug Administration (FDA) and Drug Enforcement Administration (DEA) Updates – See Appendix P**

Items to be presented by Dr. Adams, Dr. Muchmore, Chairman:

**19. Future Business\* (Upcoming Product and Class Reviews)**

***No live DUR Board meeting scheduled for August 2022. August 2022 will be a packet-only meeting.***

- A. Intravenous (IV) Iron Products
- B. Ophthalmic Anti-Inflammatory Products

C. Opioid Analgesics and Medication-Assisted Treatment (MAT) Medications

D. Topical Corticosteroids

\*Future product and class reviews subject to change.

## **20. Adjournment**

NOTE: An analysis of the atypical [Aged, Blind, and Disabled (ABD)] patient subgroup of the Oklahoma Medicaid population has been performed pertaining to all recommendations included in this DUR Board meeting packet to ensure fair and knowledgeable deliberation of the potential impact of the recommendations on this patient population.